Endo's oxymorphone receives Priority Review

FDA accepted for filing and granted Priority Review to an NDA from Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) for an extended-release, crush-resistant formulation of oxymorphone to treat moderat...